PortalPublikationenCost-of-illness of psoriasis - results of a German cross-sec...

Cost-of-illness of psoriasis - results of a German cross-sectional study

Standard

Cost-of-illness of psoriasis - results of a German cross-sectional study. / Jungen, D; Augustin, M; Langenbruch, A; Zander, N; Reich, K; Strömer, K; Thaci, D.; Purwins, S; Radtke, M; Gutknecht, M.

in: J EUR ACAD DERMATOL, Jahrgang 32, Nr. 1, 01.2018, S. 174-180.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Jungen, D, Augustin, M, Langenbruch, A, Zander, N, Reich, K, Strömer, K, Thaci, D, Purwins, S, Radtke, M & Gutknecht, M 2018, 'Cost-of-illness of psoriasis - results of a German cross-sectional study', J EUR ACAD DERMATOL, Jg. 32, Nr. 1, S. 174-180. https://doi.org/10.1111/jdv.14543

APA

Jungen, D., Augustin, M., Langenbruch, A., Zander, N., Reich, K., Strömer, K., Thaci, D., Purwins, S., Radtke, M., & Gutknecht, M. (2018). Cost-of-illness of psoriasis - results of a German cross-sectional study. J EUR ACAD DERMATOL, 32(1), 174-180. https://doi.org/10.1111/jdv.14543

Vancouver

Jungen D, Augustin M, Langenbruch A, Zander N, Reich K, Strömer K et al. Cost-of-illness of psoriasis - results of a German cross-sectional study. J EUR ACAD DERMATOL. 2018 Jan;32(1):174-180. https://doi.org/10.1111/jdv.14543

Bibtex

@article{7e8072ac25274353acf7c387b41a07e7,
title = "Cost-of-illness of psoriasis - results of a German cross-sectional study",
abstract = "BACKGROUND: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany.OBJECTIVES: The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective.METHODS: A cross-sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness-related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non-parametric tests.RESULTS: Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out-of-pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+-year-old patients were found.CONCLUSIONS: Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out-of-pocket and indirect costs towards systemic drug costs.",
keywords = "Journal Article",
author = "D Jungen and M Augustin and A Langenbruch and N Zander and K Reich and K Str{\"o}mer and D. Thaci and S Purwins and M Radtke and M Gutknecht",
note = "Bitte den Autor Jungen als internen Autor werten, wie in der Affilierung angegeben.",
year = "2018",
month = jan,
doi = "10.1111/jdv.14543",
language = "English",
volume = "32",
pages = "174--180",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - Cost-of-illness of psoriasis - results of a German cross-sectional study

AU - Jungen, D

AU - Augustin, M

AU - Langenbruch, A

AU - Zander, N

AU - Reich, K

AU - Strömer, K

AU - Thaci, D.

AU - Purwins, S

AU - Radtke, M

AU - Gutknecht, M

N1 - Bitte den Autor Jungen als internen Autor werten, wie in der Affilierung angegeben.

PY - 2018/1

Y1 - 2018/1

N2 - BACKGROUND: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany.OBJECTIVES: The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective.METHODS: A cross-sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness-related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non-parametric tests.RESULTS: Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out-of-pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+-year-old patients were found.CONCLUSIONS: Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out-of-pocket and indirect costs towards systemic drug costs.

AB - BACKGROUND: Though psoriasis poses a substantial chronic socio-economic burden, few studies have addressed the economic impact in Germany.OBJECTIVES: The objective was to evaluate the annual costs of psoriasis in Germany from the societal perspective.METHODS: A cross-sectional study was performed in randomly selected German dermatology practices and clinics in 2013/2014 using standardized questionnaires of illness-related costs. Costs were grouped by perspective and category as well as analysed by sex and age. Group differences were tested by non-parametric tests.RESULTS: Complete data were obtained from 1158 patients in 132 centres. Annual average costs for patients with psoriasis: total costs € 5543 ± € 8044, systemic treatment costs (paid by the statutory health insurances [SHI]) € 3733 ± € 7322, out-of-pocket costs € 224 ± € 406, total SHI costs € 4940 ± € 7533, direct costs € 5164 ± € 7581 and indirect costs € 379 ± € 2087. Significant higher costs in male and significant lower costs in 65+-year-old patients were found.CONCLUSIONS: Psoriasis induces a considerable economic burden. Between 2003 and 2014, costs have markedly shifted from hospital, out-of-pocket and indirect costs towards systemic drug costs.

KW - Journal Article

U2 - 10.1111/jdv.14543

DO - 10.1111/jdv.14543

M3 - SCORING: Journal article

C2 - 28857297

VL - 32

SP - 174

EP - 180

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 1

ER -